LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 10 von insgesamt 25

Suchoptionen

Artikel ; Online: Cultural and linguistic adaptation of a telephone-based cognitive-behavioral therapy (CBT) intervention to treat depression and anxiety in Hispanic cancer survivors.

Danhauer, Suzanne C / Brenes, Gretchen A / Tooze, Janet A / Abubaker, Tebianne / Thomas, Alexandra / Howard, Dianna S / Puccinelli-Ortega, Nicole / Jimenez, Karolina / Graves, Kristi D

Journal of psychosocial oncology

2023 , Seite(n) 1–15

Abstract: Purpose/objectives: The purpose of this study was to transcreate a manualized cognitive-behavioral therapy (CBT) intervention to address depression and anxiety among Hispanic cancer survivors.: Design/research approach: Stakeholders reviewed the CBT ... ...

Abstract	Purpose/objectives: The purpose of this study was to transcreate a manualized cognitive-behavioral therapy (CBT) intervention to address depression and anxiety among Hispanic cancer survivors. Design/research approach: Stakeholders reviewed the CBT workbook for language, content, and cultural relevance. We designed semi-structured interview guides to elicit intervention feedback. Sample/participants: Stakeholder participants were Hispanic cancer survivors ( Methods: Transcreation was conducted by initial translation of the workbook followed by incorporation of stakeholder feedback. A bilingual (Spanish and English) interviewer conducted stakeholder interviews. The study team discussed themes/suggestions before refining the workbook. Findings: Stakeholders reported enthusiasm for the intervention. We gathered significant feedback regarding wording, images, and resources for the workbook. Conclusion: Development of culturally appropriate mental health resources for Hispanic cancer survivors is critical. Implications for psychosocial providers or policy: By broadening research on psychosocial care to the Hispanic population, we increase the reach of evidence-based psychological care. Future research should fully evaluate the adapted CBT intervention among Hispanic survivors.
Sprache	Englisch
Erscheinungsdatum	2023-12-21
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	605892-9
ISSN	1540-7586 ; 0734-7332
ISSN (online)	1540-7586
ISSN	0734-7332
DOI	10.1080/07347332.2023.2296045
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 2006: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾

Artikel ; Online: Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen.

Reed, Daniel R / Wooster, Margaux / Isom, Scott / Ellis, Leslie R / Howard, Dianna S / Manuel, Megan / Dralle, Sarah / Lyerly, Susan / Bhave, Rupali / Powell, Bayard L / Pardee, Timothy S

Annals of hematology

2023 Band 102, Heft 4, Seite(n) 897–906

Abstract: Acute lymphoblastic leukemia (ALL) is an aggressive bone marrow cancer with disparate outcomes. Data on patient outcomes in real world settings outside of clinical trials is limited. The current study reports on outcomes for 137 ALL patients who received ...

Abstract	Acute lymphoblastic leukemia (ALL) is an aggressive bone marrow cancer with disparate outcomes. Data on patient outcomes in real world settings outside of clinical trials is limited. The current study reports on outcomes for 137 ALL patients who received an adult induction and consolidation regimen derived from the CALGB 10102 trial modified without alemtuzumab. Of the 137 patients, 32 were < 40 years old, 52 were between 40 and 59, and 53 were ≥ 60 years old. Overall, 109 (79.6%) patients achieved a complete remission (< 40: 96.1%, 40-59: 86.5%, and 62.3% ≥ 60 (p = 0.0002)). Progression free survival for the entire cohort was 13.5 months and by age was 19.8 months for less than 40, 23.4 months for 40 to 59 and 6.7 months for ≥ 60; p = 0.0002. Median survival was 22.1 months for the entire cohort (32.9 months for ages < 40, 26.6 months ages 40-59, 7.8 months ≥ 60, p < 0.001).
Mesh-Begriff(e)	Humans ; Adult ; Child, Preschool ; Infant ; Middle Aged ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Remission Induction ; Alemtuzumab/therapeutic use
Chemische Substanzen	Alemtuzumab (3A189DH42V)
Sprache	Englisch
Erscheinungsdatum	2023-03-01
Erscheinungsland	Germany
Dokumenttyp	Journal Article
ZDB-ID	1064950-5
ISSN	1432-0584 ; 0939-5555 ; 0945-8077
ISSN (online)	1432-0584
ISSN	0939-5555 ; 0945-8077
DOI	10.1007/s00277-023-05141-5
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Uh III Zs.181: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Financial burden for caregivers of adolescents and young adults with cancer.

Nightingale, Chandylen L / Canzona, Mollie R / Danhauer, Suzanne C / Reeve, Bryce B / Howard, Dianna S / Tucker-Seeley, Reginald D / Golden, Shannon L S / Little-Greene, Denisha / Roth, Michael E / Victorson, David E / Salsman, John M

Psycho-oncology

2022 Band 31, Heft 8, Seite(n) 1354–1364

Abstract: Objective: Adolescent and young adult (AYA) cancer survivors are vulnerable to cancer-related financial burden, which is likely shared by their caregivers. This study aims to enhance an existing conceptual model of financial burden by conducting concept ...

Abstract	Objective: Adolescent and young adult (AYA) cancer survivors are vulnerable to cancer-related financial burden, which is likely shared by their caregivers. This study aims to enhance an existing conceptual model of financial burden by conducting concept elicitation interviews with caregivers to generate knowledge that can be translated to inform instrumental and psychosocial support in cancer care. Methods: Qualitative concept elicitation interviews were conducted with 24 caregivers of AYA cancer survivors (caregivers of adolescents, n = 12; caregivers of emerging adults, n = 12) recruited from four sites. Constant comparative methods were used to identify themes, and results were interpreted and organized into domains of the conceptual model. We also explored COVID-19 related financial impacts among a subset (n = 12) of caregivers. Results: Seven themes emerged, which varied by age group and strengthened the conceptualization of the model. Themes centered on: (1) direct and indirect costs of cancer; (2) impact of socioeconomic status on financial burden; (3) caregiver desire to shield AYAs from distress due to financial burden; (4) strategies to manage cancer-related costs; (5) worries about AYAs' financial future; (6) seeking and receiving financial support; and (7) navigating the healthcare system. Findings also revealed that COVID-19 exacerbates financial burden for some caregivers. Conclusions: Building upon our prior work, we have adapted the conceptual model of financial burden to reflect perspectives of AYAs, oncology providers, and now, caregivers. An important next step is to develop a reliable and valid self-report measure of financial burden among caregivers of AYA cancer survivors.
Mesh-Begriff(e)	Adolescent ; COVID-19 ; Cancer Survivors/psychology ; Caregivers/psychology ; Financial Stress ; Humans ; Neoplasms/psychology ; Neoplasms/therapy ; Young Adult
Sprache	Englisch
Erscheinungsdatum	2022-04-20
Erscheinungsland	England
Dokumenttyp	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	1118536-3
ISSN	1099-1611 ; 1057-9249
ISSN (online)	1099-1611
ISSN	1057-9249
DOI	10.1002/pon.5937
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 3550: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Informed Consent for Chemotherapy: ASCO Member Resources.

Storm, Courtney / Casillas, Jacqueline / Grunwald, Hans / Howard, Dianna S / McNiff, Kristen / Neuss, Michael M

Journal of oncology practice

2018 Band 4, Heft 6, Seite(n) 289–295

Sprache	Englisch
Erscheinungsdatum	2018-02-13
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2236338-5
ISSN	1935-469X ; 1554-7477
ISSN (online)	1935-469X
ISSN	1554-7477
DOI	10.1200/JOP.0866002
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Withdrawing medically futile treatment.

Howard, Dianna S / Pawlik, Timothy M

Journal of oncology practice

2010 Band 5, Heft 4, Seite(n) 193–195

Abstract: Physicians confront clinical and ethical dilemmas when their patients wish to continue treatments they have deemed futile; they must consider ethical obligations in deciding whether treatment should be withdrawn and in transferring patients from futile ... ...

Abstract	Physicians confront clinical and ethical dilemmas when their patients wish to continue treatments they have deemed futile; they must consider ethical obligations in deciding whether treatment should be withdrawn and in transferring patients from futile treatment to supportive care.
Sprache	Englisch
Erscheinungsdatum	2010-09-07
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2236338-5
ISSN	1935-469X ; 1554-7477
ISSN (online)	1935-469X
ISSN	1554-7477
DOI	10.1200/JOP.0948501
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Seegars, Mary Beth / Woods, Ryan / Ellis, Leslie R / Bhave, Rupali Roy / Howard, Dianna S / Manuel, Megan / Dralle, Sarah / Lyerly, Susan / Powell, Bayard L / Pardee, Timothy S

Journal of hematology

2021 Band 10, Heft 1, Seite(n) 1–7

Abstract: Background: Resistance to therapy and a poor outcome characterize relapsed or refractory acute myeloid leukemia (AML). There is a clear need for additional palliative approaches with acceptable toxicities. Vincristine sulfate liposome injection (VSLI) ... ...

Abstract	Background: Resistance to therapy and a poor outcome characterize relapsed or refractory acute myeloid leukemia (AML). There is a clear need for additional palliative approaches with acceptable toxicities. Vincristine sulfate liposome injection (VSLI) confers enhanced pharmacokinetics and activity when compared to the parent compound. It is effective and well tolerated in heavily pretreated acute lymphoblastic leukemia (ALL) patients. Preclinically VSLI has activity in vincristine-resistant cancers. As relapsed or refractory AML patients would have minimal exposure to vincristine it was hypothesized that VSLI would be well tolerated and may have activity. Methods: A pilot phase II clinical trial was conducted. Five patients with relapsed or refractory disease were treated using the Food and Drug Administration (FDA)-approved dose and schedule. Results: Of the five patients treated none completed more than one cycle; there were no responses and two patients did not complete one cycle of therapy. Surprisingly, three of the five patients had treatment-related constipation, and two had neuropathy consistent with the known toxicities of VSLI. Given the toxicity and lack of response, the trial was terminated early. Conclusions: VSLI had no activity against relapsed or refractory AML in this limited, single institution dataset.
Sprache	Englisch
Erscheinungsdatum	2021-02-06
Erscheinungsland	Canada
Dokumenttyp	Journal Article
ZDB-ID	2662519-2
ISSN	1927-1220 ; 1927-1220
ISSN (online)	1927-1220
ISSN	1927-1220
DOI	10.14740/jh771
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.

Anderson, Rebecca / Miller, Lance D / Isom, Scott / Chou, Jeff W / Pladna, Kristin M / Schramm, Nathaniel J / Ellis, Leslie R / Howard, Dianna S / Bhave, Rupali R / Manuel, Megan / Dralle, Sarah / Lyerly, Susan / Powell, Bayard L / Pardee, Timothy S

Nature communications

2022 Band 13, Heft 1, Seite(n) 1673

Abstract: Devimistat is a TCA cycle inhibitor. A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response rates. Here we report the results of a single ... ...

Abstract	Devimistat is a TCA cycle inhibitor. A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response rates. Here we report the results of a single arm phase II study (NCT02484391). The primary outcome of feasibility of maintenance devimistat following induction and consolidation with devimistat in combination with high dose cytarabine and mitoxantrone was not met, as maintenance devimistat was only administered in 2 of 21 responders. The secondary outcomes of response (CR + CRi) and median survival were 44% (21/48) and 5.9 months respectively. There were no unexpected toxicities observed. An unplanned, post-hoc analysis of the phase I and II datasets suggests a trend of a dose response in older but not younger patients. RNA sequencing data from patient samples reveals an age-related decline in mitochondrial gene sets. Devimistat impairs ATP synthesis and we find a correlation between mitochondrial membrane potential and sensitivity to chemotherapy. Devimistat also induces mitochondrial reactive oxygen species and turnover consistent with mitophagy. We find that pharmacological or genetic inhibition of mitochondrial fission or autophagy sensitizes cells to devimistat. These findings suggest that an age related decline in mitochondrial quality and autophagy may be associated with response to devimistat however this needs to be confirmed in larger cohorts with proper trial design.
Mesh-Begriff(e)	Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Caprylates ; Cytarabine/therapeutic use ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Mitoxantrone ; Sulfides ; Treatment Outcome
Chemische Substanzen	Caprylates ; Sulfides ; Cytarabine (04079A1RDZ) ; Mitoxantrone (BZ114NVM5P) ; devimistat (E76113IR49)
Sprache	Englisch
Erscheinungsdatum	2022-03-30
Erscheinungsland	England
Dokumenttyp	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-022-29039-4
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Efficacy of 10-day decitabine in acute myeloid leukemia.

Bouligny, Ian M / Mehta, Vivek / Isom, Scott / Ellis, Leslie R / Bhave, Rupali R / Howard, Dianna S / Lyerly, Susan / Manuel, Megan / Dralle, Sarah / Powell, Bayard L / Pardee, Timothy S

Leukemia research

2021 Band 103, Seite(n) 106524

Abstract: The azanucleotide decitabine is used in the treatment of acute myeloid leukemia (AML). Studies have shown conflicting results with 10-day regimens used in previously untreated AML patients. Additionally, there is little data on 10-day decitabine regimens ...

Abstract	The azanucleotide decitabine is used in the treatment of acute myeloid leukemia (AML). Studies have shown conflicting results with 10-day regimens used in previously untreated AML patients. Additionally, there is little data on 10-day decitabine regimens in the relapsed setting. This study investigated outcomes of 108 adult patients with AML in the upfront and relapsed setting treated with a 10-day decitabine regimen. In the upfront group, the overall response rate (ORR, CR + CRi) was 36.1% and the median overall survival (OS) was 6.6 months, while the relapsed/refractory group had an ORR of 25% with an OS of 4.8 months. When analyzed with respect to cytogenetics, the upfront group featured an ORR of 28.1% with an OS of 9.4 months in the intermediate cytogenetic cohort compared to a 40.5% ORR and an OS of 5.4 months in the unfavorable cytogenetic cohort. An analysis of the relapsed/refractory group demonstrated an ORR of 26.3% with an OS of 7.9 months for intermediate cytogenetics versus 25.0% with an OS of 1.8 months in the unfavorable cohort. While these response rates are similar to previously published data, the median OS appears shorter.
Mesh-Begriff(e)	Adult ; Aged ; Aged, 80 and over ; Decitabine/administration & dosage ; Disease-Free Survival ; Female ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Survival Rate ; Time Factors
Chemische Substanzen	Decitabine (776B62CQ27)
Sprache	Englisch
Erscheinungsdatum	2021-02-12
Erscheinungsland	England
Dokumenttyp	Clinical Trial ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	752396-8
ISSN	1873-5835 ; 0145-2126
ISSN (online)	1873-5835
ISSN	0145-2126
DOI	10.1016/j.leukres.2021.106524
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 1321: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Stakeholder-informed conceptual framework for financial burden among adolescents and young adults with cancer.

Danhauer, Suzanne C / Canzona, Mollie / Tucker-Seeley, Reginald D / Reeve, Bryce B / Nightingale, Chandylen L / Howard, Dianna S / Puccinelli-Ortega, Nicole / Little-Greene, Denisha / Salsman, John M

Psycho-oncology

2021 Band 31, Heft 4, Seite(n) 597–605

Abstract: Background: Cancer and its treatments can result in substantial financial burden that may be especially distressing for adolescents and young adults (AYAs) since they are at a developmental stage focused on completing one's education and establishing ... ...

Abstract	Background: Cancer and its treatments can result in substantial financial burden that may be especially distressing for adolescents and young adults (AYAs) since they are at a developmental stage focused on completing one's education and establishing independence. The purpose of this study was to develop a conceptual model of financial burden among AYA cancer patients to inform development of a financial burden measure. Methods: In-depth concept elicitation interviews were conducted with a purposive-selected stakeholder sample (36 AYAs and 36 AYA oncology health care providers). The constant comparative method was used to identify themes that illustrate AYAs' experience of financial burden by stakeholder groups. Results: Eleven financial burden themes emerged: (1) impact of socioeconomic status and age; (2) significant cancer costs; (3) indirect cost "ripple effects"; (4) limited awareness of costs (adolescents); (5) emotional impact; (6) feeling overwhelmed navigating the health care system; (7) treatment decision modifications; (8) reducing spending; (9) coping strategies; (10) financial support; and (11) long-lasting impact. The conceptual model highlights the importance of material, psychosocial, and behavioral domains of financial burden with an emphasis on phase along the cancer continuum and developmental stage in the experience of financial burden for AYAs. Conclusions: Issues presented in the voice of AYA patients and providers highlight the profound impact of financial burden in this survivor group. The next step in this work will be to develop and test a patient-reported measure of financial burden among AYA cancer survivors.
Mesh-Begriff(e)	Adaptation, Psychological ; Adolescent ; Cancer Survivors/psychology ; Financial Stress ; Humans ; Neoplasms/psychology ; Neoplasms/therapy ; Survivors ; Young Adult
Sprache	Englisch
Erscheinungsdatum	2021-11-05
Erscheinungsland	England
Dokumenttyp	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	1118536-3
ISSN	1099-1611 ; 1057-9249
ISSN (online)	1099-1611
ISSN	1057-9249
DOI	10.1002/pon.5843
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 3550: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel: SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).

Hill, Joshua A / Martens, Michael J / Young, Jo-Anne H / Bhavsar, Kavita / Kou, Jianqun / Chen, Min / Lee, Lik Wee / Baluch, Aliyah / Dhodapkar, Madhav V / Nakamura, Ryotaro / Peyton, Kristin / Howard, Dianna S / Ibrahim, Uroosa / Shahid, Zainab / Armistead, Paul / Westervelt, Peter / McCarty, John / McGuirk, Joseph / Hamadani, Mehdi /

DeWolf, Susan / Hosszu, Kinga / Sharon, Elad / Spahn, Ashley / Toor, Amir A / Waldvogel, Stephanie / Greenberger, Lee M / Auletta, Jeffery J / Horowitz, Mary M / Riches, Marcie L / Perales, Miguel-Angel

medRxiv : the preprint server for health sciences

2024

Abstract: Background: The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood.: Objective: To describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after ...

Abstract	Background: The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood. Objective: To describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after cellular therapy. Design: Multicenter prospective observational study. Setting: 34 centers in the United States. Participants: 466 allogeneic hematopoietic cell transplant (HCT; n=231), autologous HCT (n=170), or chimeric antigen receptor T cell (CAR-T cell) therapy (n=65) recipients enrolled between April 2021 and June 2022. Interventions: SARS-CoV-2 vaccination as part of routine care. Measurements: We obtained blood prior to and after vaccinations at up to five time points and tested for SARS-CoV-2 spike (anti-S) IgG in all participants and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains, as well as SARS-CoV-2-specific T cell receptors (TCRs), in a subgroup. Results: Anti-S IgG and neutralizing antibody responses increased with vaccination in HCT recipients irrespective of vaccine initiation timing but were unchanged in CAR-T cell recipients initiating vaccines within 4 months. Anti-S IgG Limitations: The majority of participants were adults and received mRNA vaccines. Conclusions: These data support starting mRNA SARS-CoV-2 vaccination three to four months after allogeneic HCT, autologous HCT, and CAR-T cell therapy. Funding: National Marrow Donor Program, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Novartis, LabCorp, American Society for Transplantation and Cellular Therapy, Adaptive Biotechnologies, and the National Institutes of Health.
Sprache	Englisch
Erscheinungsdatum	2024-01-25
Erscheinungsland	United States
Dokumenttyp	Preprint
DOI	10.1101/2024.01.24.24301058
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾

Zum Seitenanfang

Ihre letzten Suchen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED